Kornimate/medical-research-clean huggingface dataset:
effects of blood flow of venoarterial extracorporeal membrane oxygenation life support on microcirculation

Conditions: Circulatory Failure

Summary: extra-corporeal membrane oxygenation (ecmo) life support system can provide both cardiac and respiratory support to patients with heart and respiratory failure. it can save time for these patients to regain organ function or to receive transplantation. both the investigators' team and ince et al. from the netherland found that the microcirculatory dysfunction is more severe in ecmo non-survivors. the next step of research is to find out the key factors that affect microcirculation in ecmo patients. because the blood flow supplied by the venoarterial ecmo (va-ecmo) is directly related to macrocirculation, this study aims to investigate the effect of adjustment of va-ecmo blood flow on microcirculation. the investigators hope that the results of this study can help the medical team to improve the quality of ecmo care.

after evaluation, explanation, and acquisition of agreement, the sublingual microcirculation will be examined within 24 h and at 48 h after placement of va-ecmo. the va-ecmo blood flow will be recorded, and the baseline microcirculation will be examined. after the ecmo technician adjusting the ecmo flow, sublingual microcirculation will be examined 2 minutes after each adjustment, and the change of ecmo blood flow will be recorded. when the ecmo team plans to weaning off the ecmo within 72 h, the sublingual microcirculation will be examined. the va-ecmo blood flow will be reduced by ecmo technician, and sublingual microcirculation will be examined 2 minutes after each adjustment of the blood flow. the ecmo parameters, medications, and clinical data will be recorded, and the prognosis will be followed up on the 28th day.

Eligibility criteria:
inclusion criteria: * patients who require venoarterial extra-corporeal membrane oxygenation (ecmo) life support exclusion criteria: * who can not take an examination of sublingual microcirculation within 24 hours after placement of venoarterial ecmo support * non-native speakers
partial pulpotomy on caries free human teeth

Conditions: Dentin Bridge; Pulpitis

Summary: the purpose of this study is to compare the human pulp response to partial pulpotomy using white proroot mta or iroot bp in the terms of dentinal bridge formation and inflammation.

this will be a randomized single blind clinical trial. setting and conduct: twenty caries free premolar teeth from fifteen patients assigned for orthodontic extraction will be included. participants including major eligibility criteria: their parents need to sign an informed form, patients shouldn't have any systematic complication, the teeth should be free of any symptom, caries and decalcification and should reveal a normal response to pulp sensitivity tests, no mobility or swelling in the surrounding soft tissues, sensitivity on palpation or percussion should be present. intervention: a class one cavity will be prepared and the depth will be increased until the pulp exposure occurs. one millimeter of the coronal pulp will be removed. then the exposure site will be covered using two pulpotomy agents: white proroot mta as control group and iroot bp. after six weeks (42 days) the teeth will be extracted after radiographic and clinical examination to find any sign of swelling, abscess or sinus tract. main outcome measures (variables): the teeth will be sectioned and examined to compare the presence of dentinal bridge, its thickness and feature in the terms of tunnel defect formation. the underlying pulp will be assessed and graded according to the degree of inflammation as follows: grade 0 no inflammation, grade 1 mild inflammation, grade 2 moderate inflammations, grade 3 severe inflammation, grade 4 abscess formation or necrosis. our criteria are based on iso 7405.

Eligibility criteria:
inclusion criteria: * patients who are assigned to extract two premolar teeth in one jaw for orthodontic treatment plan. * their parents need to read and sign a fully informed form. * they shouldn't have any systematic complication or take any medicine during the period of study. * the teeth need to be free of any symptom, caries and decalcification * they should give a normal response to pulp sensitivity tests (cold test) compared to the control tooth on the same quadrant. * the teeth need to be free of mobility or swelling in the surrounding soft tissues and any sensitivity on palpation or percussion. * on radiographic examination no apical lucency or pdl widening should be detected. exclusion criteria: * tooth crack * tooth filling * any caries * hypocalcification * the teeth showing apical lucency * pdl widening on radiography * sensitivity to cold, heat or bite * the responses beyond the normal limits to pulp vitality testing * any medicine consumption

Keywords: partial pulpotomy cvek pulpotomy mta irootbp dentin bridge
pilot study of the ablative fractional co2 laser in hypertrophic scars in adult burn patients

Conditions: Burns

Summary: this is a randomized, controlled, within-patient, single-blinded, pilot study that will evaluate the impact of laser treatment on burn hsc relative to self-matched control scars. the studied primary outcomes of treatment are scar pliability, thickness, vascularity, pain, itch and patient satisfaction.

prior to treatment initiation, two independent scars sites will be selected and an anatomically- on each individual. at the selected treatment site the scar will be treated with the core fractional co2 laser participants will receive 3 treatment sessions scheduled 4 weeks apart. the scar sites will be evaluated at baseline, immediately before the 3rd treatment and 12 weeks after their final treatment session.

Eligibility criteria:
inclusion criteria: * fitzpatrick skin type \<iv (37), * have sustained a thermal burn injury, * have at least 2 independent sites that show clinical evidence of hsc, * are 2 months or more post-injury. exclusion criteria: * subjects with skin phototypes iv or higher, * with history of keloidal scarring, * who have coagulation disorder, * are taking immunosuppressive medications, * if the mechanism of injury is an electrical, chemical, or cold injury, * any underlying active skin disease, * have taken oral isotreinoin within the last 6 months, * photosensitivity or have taken photosensitizing medications, * pregnancy, * previous treatment with dermabrasion, chemical peel, laser or intense pulsed light treatment
abuse liability of pregabalin and its effects on benzodiazepine withdrawal symptoms

Conditions: Substance-Related Disorders

Summary: the purpose of this study is to determine if a single dose of pregabalin 300mg in patients receiving medications for sedative-hypnotic withdrawal symptoms will produce meaningful differences in measures of "drug liking" and "drug high" as compared to placebo.

pregabalin is currently being explored as a pharmacotherapy for substance use disorders. open-labeled, uncontrolled studies indicate modest efficacy of pregabalin in benzodiazepine withdrawal symptom management and as a long-term benzodiazepine dependence treatment. concurrently, there is increasing information from case reports and adverse drug event registries regarding pregabalin abuse in patients with substance use disorders. given that the abuse liability of pregabalin has not been clearly established, nor its effects on benzodiazepine withdrawal symptoms in inpatients, this study is a randomized, double-blind, placebo-controlled, cross-over, abuse liability study of a single dose of pregabalin 300mg, nested within a randomized,double-blind placebo-controlled, feasibility study evaluating pregabalin's effects on withdrawal symptoms in inpatients undergoing medically-assisted withdrawal from benzodiazepine, zopiclone or zolpidem.

Eligibility criteria:
inclusion criteria: * admitted to the medical withdrawal unit at the centre for addiction and mental health for medically assisted withdrawal from benzodiazepines, zopiclone and/or zolpidem * willing and capable to give written informed consent exclusion criteria: * patients who are hypersensitive to pregabalin or to any ingredient in the formulation or component of the container. * pregnant or nursing women * renal impairment (creatinine clearance less than 60ml/min) * history of angioedema, or taking drugs associated with angioedema (e.g., ace-inhibitors). * currently taking pregabalin or gabapentin * currently taking thiazolidinedione antidiabetic agents (e.g., rosiglitazone, pioglitazone) * previous history of pregabalin or gabapentin abuse
visceral artery aneurysm embolization by the penumbra ruby™ coil system

Conditions: Visceral Artery Aneurysms; Arteriovenous Malformations

Summary: the primary objective of this study is to gather post market data on the penumbra ruby coil system in the treatment of visceral artery aneurysms and arteriovenous malformations. this study is a prospective, multi-center study of patients with visceral artery aneurysms and visceral arteriovenous malformations who are treated by the penumbra ruby coil system. data for each patient are collected up to 12 months post-procedure for the study.


Eligibility criteria:
inclusion criteria: * patients enrolled in this study must be those treated according to the cleared indication for the penumbra ruby coil system for visceral arterial and venous embolizations. exclusion criteria: * patients in whom endovascular embolization therapies other than penumbra coils are used will be excluded from this study.

Keywords: visceral artery aneurysms arteriovenous malformations penumbra ruby coil system
exercise therapy for osteoarthritis pain: how does it work?

Conditions: Knee Osteoarthritis

Summary: international guidelines recommend exercise as the first choice treatment for knee osteoarthritis (koa). muscle strengthening training (mst) and behavioural graded activity (bga) show comparable effects on koa pain, but the mechanisms of action are unclear. understanding these mechanisms is necessary to tailor exercise therapy towards specific mediators and thereby optimize treatment effects. based on previous studies, both exercise-induced anti-inflammation and endogenous analgesia are promising pathways for pain reduction after exercise therapy. this study aims to examine (anti)-inflammation and endogenous analgesia as mediators for the effect of mst and/or bga on pain in patients with koa. therefore, a 3-arm randomized clinical trial is established: 12 weeks of muscle strengthening training, behavioural graded activity or control. mediator analysis will be performed. unravelling the mechanisms of action of exercise therapy in koa will not only be extremely valuable for researchers, but also for exercise immunology and pain scientists. the results of this research will also find their way into clinical practice: thanks to the current project, tailoring exercise therapy programs towards specific mechanistic factors and thereby optimizing treatment effects will be at the horizon for patients suffering from koa.


Eligibility criteria:
inclusion criteria: 1. koa according to the clinical american college of rheumatology (acr) criteria. the clinical acr criteria for koa are: knee pain and at least 3 of the 6 following features: age ≥50, morning stiffness \<30 minutes, crepitus, bony tenderness, bony enlargement, no palpable warmth. koa will be confirmed with radiographs, including anterior-posterior (ap) and medio-lateral (ml) radiographs for imaging the tibiofemoral joint, and an axial view for imaging the patellofemoral joint. kellgren and lawrence (k\&l) grading system for oa will be applied, with k\&l grade 2 or higher defined as oa; radiographic koa is defined as definite osteophytes and possible joint space narrowing. 2. pain, nominated by the patient as 3 /10 or higher on a visual analogue scale on most days of the last 3 months 3. aged ≥ 50 years. exclusion criteria: 1. treatment with exercise therapy or joint infiltrations (e.g., corticosteroids, hyaluronic acid) in the preceding 6 months; 2. being on a waiting list for knee replacement; 3. any contra-indication for exercise therapy as established by the treating physician; 4. corticosteroid infiltrations in the last 6 months; 5. cognitive impairment (unable to understand the test instructions and/or mini mental state examination score \<23/30); 6. unable to understand the dutch language; 7. inflammation unrelated to oa (e.g. due to acute or chronic infection) established by crp\>10mg/l. 8. presence of a disorder and/or medication that influences pain and/or the immune system

Keywords: osteoarthritis exercise acute effects inflammation endogenous hypoalgesia
to demonstrate the relative bioavailability of geneva and dista (prozac) 20 mg fluoxetine hydrochloride capsules (pulvules) in healthy adult males under fasting conditions

Conditions: Depression

Summary: to demonstrate the relative bioavailability of geneva and dista (prozac) 20 mg fluoxetine hydrochloride capsules (pulvules) in healthy adult males under fasting conditions.


Eligibility criteria:
inclusion criteria: * no clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. exclusion criteria: * positive test results for hiv or hepatitis b or c. * treatment for drug or alcohol dependence.
a phase ii controlled trial of velafermin for prevention of oral mucositis

Conditions: Oral Mucositis; Stomatitis

Summary: cg53135-05 (velafermin), a recombinant human fibroblast growth factor-20 (rhfgf-20) protein, is under investigation for the prevention of oral mucositis. oral mucositis is a commonly occurring side effect of high-dose chemotherapy in patients undergoing autologous hematopoietic stem cell transplant. the objective of this phase ii trial is to confirm the safety and efficacy of cg53135-05 (velafermin) when administered as a single dose to patients at risk for developing oral mucositis.


Eligibility criteria:
inclusion criteria: * age 18 years or older * patients with multiple myeloma or lymphoma receiving myeloablative ct with or without tbi that require autologous stem cell support. the ct regimens are limited to high dose melphalan (200 mg/m2) as a single agent, beam, or tbi with cyclophosphamide or vp-16. * adequate organ function that meets institutional requirements for autologous stem cell transplant. a minimum cd34+ cell dose of 2x106 /kg based on ideal body weight (ibw) has been or will be infused. * ecog performance score of 2 or less * signed informed consent form (icf) exclusion criteria: * premenopausal female patients who are pregnant, lactating or are likely to become pregnant * patients diagnosed with active sero-positive acquired immunodeficiency syndrome (aids) or hepatitis b/ c * patients with known hypersensitivity to recombinant protein therapeutics * patients who have taken velafermin (cg53135-05) previously * patients who have taken palifermin in the past 90 days * patients who have taken other investigational drugs in the past 30 days * patients who have untreated symptomatic dental infection * patients with a history of sensitivity or allergy to e. coli-derived products * patients with who grade 3 or 4 om at the time of randomization * patients who are sensitive or allergic to g-csf, fluconazole or acyclovir or equivalent * patients with altered mental status precluding understanding of the informed consent process and/or completion of the necessary assessments * patients with baseline creatinine level greater than or equal to 3 or any patient with renal insufficiency requiring dialysis.

Keywords: oral mucositis hematologic autologous stem cell transplant velafermin stomatitis oncology - supportive care mouth diseases
bronchoreversibility test in asthmatic children and correlation with diagnostic criteria proposed by the gina guidelines

Conditions: Pediatric Asthma

Summary: since 2015, gina (global initiative on asthma) guidelines were modified and adapted to better fit the pediatric population. asthma diagnosis is mainly based on the results of pft (pulmonary function tests) and broncho-reversibility test in adult. gina guidelines modified the requirements to reach a diagnosis of asthma in children, based on the reversibility test. gina guideline propose an increase of 12% of the fev1 is considered as the diagnostic criterium for asthma in pediatrics. nevertheless, in clinical practice, most physicians base their diagnosis of asthma in children on the clinical signs presented by the patient and on the efficacy of the prescribed therapy. also, the spirometric criterium is not sufficiently corroborated by clinical studies. no research has ever looked for the results of bronchoreversibility test in patients receiving a clinical diagnosis of asthma. for this reason, in children with a clinical diagnosis of asthma, the investigators want to look for the results of the bronchoreversibility test and validate that an increase of 12% of the fev1 correlate with a physician-driven diagnosis of asthma in pediatrics. for further analysis the investigatorswill evaluate also the reversibility of small airways (fef25-75) and the z-score of the results of the pft in these children.


Eligibility criteria:
inclusion criteria: * children aged between 5 and 18 years * children with a diagnosis of asthma undergoing a pft and a bronchoreversibility test on the day of the diagnosis * children evaluated at the university hospital of montpellier (france), or at the pediatric allergy unit of the university hospital of pavia (italy) exclusion criteria: * children not able to perform a pft * children taking drugs that could affect the results of a pft * children included in other trials that don't allow them to be included in the present one

Keywords: bronchodilation test gina reversibility criteria
national evaluation of pi-based 2nd line efficacy in cambodia

Conditions: HIV

Summary: medium and long term efficacy of pi-based 2nd line antiretroviral (arv) therapy in cambodia is poorly documented when the numbers of patients on treatment and their duration are increasing. for patients in treatment failure , there is no alternative arv regimen available to date. this operational research aims to evaluate the cambodian national program pi-based 2nd line antiretroviral regimen to assess the proportion of treatment failure and drug resistance ;identify the structural and individual factors associated with treatment failure ; design alternative salvage arv regimens.


Eligibility criteria:
inclusion criteria: * hiv infection * age above 18 years * current pi based 2nd line arv treatment since at least 6 months * willing to participate and consent signature exclusion criteria: * ongoing pi based 2nd line regimen for less that 6 months at time of study intake

Keywords: hiv pi based 2nd line arv treatment virological failure drug resistance cambodia adherence
at-home testing refraction results with best corrected visual acuity (bcva) outcomes in adults

Conditions: Visual Impairment; Myopia; Hyperopia; Astigmatism

Summary: this study is aimed at examining the bcva from try-on glasses constructed from measurements from the eyeque visioncheck.

this study is aimed at examining the bcva from try-on glasses constructed from measurements from the eyeque visioncheck. the refraction measurements that users obtain from the visioncheck are from testing at-home and without additional guidance other than that normally provided to those purchasing the device.

Eligibility criteria:
inclusion criteria: 1. male or female 2. ages 30+ 3. had purchased an eyeque refraction device. 4. obtained egn's from the eyeque refraction device. 5. ordered try-on glasses based on eyeque eyeglass numbers. 6. allow use for this study the visioncheck refraction and try-on glasses measurements, taken prior to study participation. subject exclusion criteria, subjects that by self-report: 1. do not have a command of the english language. 2. lack the ability to follow instructions. 3. lack binocular vision. 4. are color-blind.
prospective and retrospective cohort study to find new prognostic factors and therapeutic targets in patients with newly diagnosed or relapsed malignant hematologic disorder excluding acute leukemia

Conditions: Malignant Hematologic Disorder

Summary: the purpose of this study is to elucidate the factors which are associated with the diagnosis and predict prognosis and therapeutic targets by collecting specimens of tissue sample, peripheral blood, and bone marrow aspirates at the time of diagnosis or relapse/refractory in patients with malignant hematologic disorders except acute leukemia. this study is eligible for patients who are diagnosed with malignant hematologic disorders except acute leukemia or who will have diagnostic procedure with suspicion of having hematologic malignancy. prospective cohort is for patients who are not in treatment for hematologic malignancy. retrospective cohort is for patients who are diagnosed and in treatment.


Eligibility criteria:
inclusion criteria: * the patients with malignant hematologic disorders except acute leukemia who are diagnosed pathologically according to the revised 2008 who classification of tumours of haematopoietic and lymphoid tissue or who will have diagnostic procedure with suspicion of having hematologic malignancy. * any gender and age ≥ 19 years * written informed consent * diagnosed after 2005-01-01 in retrospective cohort group. exclusion criteria: * patients who cannot understand or disagree the informed consent * patients who diagnosed with acute leukemia
early diagnosis of oral cancer by detecting p16 methylation

Conditions: Moderate Epithelial Dysplasia; Mild Epithelial Dysplasia

Summary: the purpose of this study is to verify the function of p16 methylation diagnostic reagents in early diagnosis of oral cancer.

background:oral epithelial dysplasia (oed) is one of the common precancerous lesions among chinese adults. to investigate the clinical predictive value of p16 methylation diagnostic reagents in the early diagnosis of oral cancer, the investigators carried out the prospective multi-center double-blind cohort study. methods:180 patients with histologically confirmed mild or moderate oed were included in the present study. the investigators using p16 methylation diagnostic reagents to analysis of the p16 methylation status in these patients. building two follow-up queue by p16-methylated and p16-unmethylated. the statistical analysis used sas6.12 software. all p-values were two-sided. p\<0.05 was considered to test for statistical significance difference.

Eligibility criteria:
inclusion criteria: * histopathological diagnosis of oral lesions meet the epithelial diagnostic criteria for mild to moderate grade oed * no local area stimulate by residual root and crown, sharp cusp, poor restoration and biting cheek or lips * without the oce treatment history by laser , radiation or chemical * be able to sign the informed consent exclusion criteria: * histopathological diagnosis of oral lesions do not meet the epithelium of mild to moderate dysplasia diagnostic criteria; histological diagnosis of severe grade oed or malignant disease * pregnancy or breast-feeding women * serious heart, lung, liver , kidney and other systemic diseases * local area stimulate by residual root and crown, sharp cusp, poor restoration and biting cheek or lips * oed treatment history by laser, radiotherapy, or chemotherapy * tumor and psychiatric patients * patients are unable to cooperate

Keywords: oral epithelial dysplasia p16 methylation diagnostic reagents early diagnosis